ATE460935T1 - Besonders nützliche zusammensetzungen für die behandlung oder prävention des metabolischen syndroms - Google Patents

Besonders nützliche zusammensetzungen für die behandlung oder prävention des metabolischen syndroms

Info

Publication number
ATE460935T1
ATE460935T1 AT05708123T AT05708123T ATE460935T1 AT E460935 T1 ATE460935 T1 AT E460935T1 AT 05708123 T AT05708123 T AT 05708123T AT 05708123 T AT05708123 T AT 05708123T AT E460935 T1 ATE460935 T1 AT E460935T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
metabolic syndrome
enzyme inhibitor
oxidase enzyme
Prior art date
Application number
AT05708123T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34828616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE460935(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FI20040136A external-priority patent/FI20040136A0/fi
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Application granted granted Critical
Publication of ATE460935T1 publication Critical patent/ATE460935T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
AT05708123T 2004-01-30 2005-01-19 Besonders nützliche zusammensetzungen für die behandlung oder prävention des metabolischen syndroms ATE460935T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20040136A FI20040136A0 (fi) 2004-01-30 2004-01-30 Erityisesti diabeetikoille soveltuvia koostumuksia
US57889604P 2004-06-14 2004-06-14
PCT/FI2005/000035 WO2005072738A1 (en) 2004-01-30 2005-01-19 Compositions useful especially for treatment or prevention of metabolic syndrome

Publications (1)

Publication Number Publication Date
ATE460935T1 true ATE460935T1 (de) 2010-04-15

Family

ID=34828616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05708123T ATE460935T1 (de) 2004-01-30 2005-01-19 Besonders nützliche zusammensetzungen für die behandlung oder prävention des metabolischen syndroms

Country Status (12)

Country Link
EP (1) EP1708711B1 (de)
JP (1) JP2007519688A (de)
AT (1) ATE460935T1 (de)
CA (1) CA2549029A1 (de)
CY (1) CY1110194T1 (de)
DE (1) DE602005019974D1 (de)
DK (1) DK1708711T3 (de)
ES (1) ES2342409T3 (de)
PL (1) PL1708711T3 (de)
PT (1) PT1708711E (de)
SI (1) SI1708711T1 (de)
WO (1) WO2005072738A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
FI20060768A0 (fi) * 2006-08-28 2006-08-28 Faron Pharmaceuticals Oy Erityisesti metabolia-oireyhtymän hoitoon tai ehkäisyyn soveltuvia koostumuksia
ITMI20050891A1 (it) * 2005-05-17 2006-11-18 Greenleaf S R L Formulazioni per il trattamento di psoriasi
CN103120690A (zh) * 2007-10-19 2013-05-29 株式会社·R-技术上野 用于治疗白内障的药物组合物
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
JP5640983B2 (ja) 2009-09-16 2014-12-17 アステラス製薬株式会社 グリシン化合物
WO2016019413A1 (en) 2014-08-04 2016-02-11 Commonwealth Scientific And Industrial Research Organisation Methods for formulating dietary foodstuffs
CN108299485B (zh) * 2018-02-09 2020-05-12 湖北大学 一种用于检测活细胞内过氧化氢的荧光探针及其制备方法和应用
US20220354847A1 (en) * 2019-09-26 2022-11-10 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Thiamine therapy for fatty liver associated diseases
CN110713986B (zh) * 2019-11-12 2023-05-12 江南大学 一株维生素b1单克隆抗体杂交瘤细胞株cbdd及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5441883A (en) * 1977-09-05 1979-04-03 Takeda Chem Ind Ltd Thiamine derivative and its preparation
US4558050A (en) * 1984-03-01 1985-12-10 University Of Florida Treatment of metabolic disorders with dichloroacetate-thiamine preparations
JPH01104142A (ja) * 1987-10-19 1989-04-21 Seibutsu Shigen Kenkyusho:Kk 消臭機能性食品及びその製造法
JP3942257B2 (ja) * 1998-01-06 2007-07-11 希能 澤口 機能性食品
AU2001282163B2 (en) † 2000-07-05 2004-12-09 Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases
DE10043802A1 (de) 2000-09-06 2002-03-14 Daimler Chrysler Ag Achse für Fahrzeuge, insbesondere Nutzfahrzeuge
AU2002214505A1 (en) * 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
JP2002193826A (ja) * 2000-12-26 2002-07-10 Fancl Corp 強壮・強精組成物
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
CA2514573A1 (en) † 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors

Also Published As

Publication number Publication date
DK1708711T3 (da) 2010-06-14
PL1708711T3 (pl) 2010-10-29
PT1708711E (pt) 2010-06-01
EP1708711B1 (de) 2010-03-17
SI1708711T1 (sl) 2010-07-30
JP2007519688A (ja) 2007-07-19
EP1708711A1 (de) 2006-10-11
CY1110194T1 (el) 2015-01-14
WO2005072738A1 (en) 2005-08-11
ES2342409T3 (es) 2010-07-06
CA2549029A1 (en) 2005-08-11
DE602005019974D1 (de) 2010-04-29

Similar Documents

Publication Publication Date Title
ATE460935T1 (de) Besonders nützliche zusammensetzungen für die behandlung oder prävention des metabolischen syndroms
DE602006015042D1 (de) Nahrungsergänzungsmittel für hiv-patienten
MX2010002404A (es) Composiciones de grasa solida que contiene un acido graso poliinsaturado y usos y produccion de las mismas.
TW200420288A (en) Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
ATE511764T1 (de) Silizium enthaltende lebensmittel
ATE541470T1 (de) Physiologische kühlzusammensetzungen
DE502006004798D1 (de) Nahrungsergänzungsmittel oder functional food enthaltend öl-kombination
ATE375810T1 (de) Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
BRPI0820431A2 (pt) Produção de produtos alimentícios com realce no refrigério mental e bucal
ATE487475T1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
ATE400272T1 (de) Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
WO2007035933A3 (en) Composition for reducing fat megration in food products
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
MX2013008887A (es) Papas fritas con bajo contenido de aceite en la superficie y elaboracion de las mismas.
MX2013004371A (es) Cisteina y consumo de alimentos.
FI20020265A (fi) Elintarvike
TW200640898A (en) Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
WO2012081831A3 (en) Composition comprising the extract of loranthus yadoriki sieb having monoamine oxidase-inhibiting activity
JP2006089487A5 (de)
DE602007008943D1 (de) Kochvorrichtung
JO2666B1 (en) Use of agomelatine for medications to treat bilateral mental disorders
WO2005037258A3 (en) Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
DK1729598T3 (da) Præparat, anvendelse af et præparat og en fremgangsmåde til forebyggelse af fedtabsorption
Choi et al. How to use health and nutrition-related (HNR) claims effectively on food advertising: comparison of benefit-seeking, risk-avoidance, and taste appeals on different food categories

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1708711

Country of ref document: EP